Brokerages expect Radius Health (NASDAQ:RDUS) to announce earnings of ($1.40) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Radius Health’s earnings, with the lowest EPS estimate coming in at ($1.56) and the highest estimate coming in at ($1.32). Radius Health reported earnings of ($1.32) per share in the same quarter last year, which indicates a negative year over year growth rate of 6.1%. The business is scheduled to issue its next earnings results on Monday, May 7th.
According to Zacks, analysts expect that Radius Health will report full-year earnings of ($5.11) per share for the current financial year, with EPS estimates ranging from ($5.85) to ($3.91). For the next year, analysts forecast that the company will post earnings of ($4.18) per share, with EPS estimates ranging from ($4.63) to ($3.62). Zacks’ EPS averages are an average based on a survey of analysts that cover Radius Health.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.16). The company had revenue of $7.66 million during the quarter, compared to the consensus estimate of $7.37 million. During the same period in the previous year, the business posted ($1.22) EPS. The business’s revenue was up 666.0% compared to the same quarter last year.
In other Radius Health news, major shareholder Growth N. V. Biotech acquired 75,000 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was purchased at an average price of $34.38 per share, with a total value of $2,578,500.00. Following the completion of the purchase, the insider now directly owns 5,773,799 shares in the company, valued at approximately $198,503,209.62. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 80,000 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was acquired at an average cost of $32.52 per share, with a total value of $2,601,600.00. Following the purchase, the insider now owns 5,853,799 shares of the company’s stock, valued at $190,365,543.48. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 205,000 shares of company stock valued at $7,009,100. Corporate insiders own 15.00% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in RDUS. Cubist Systematic Strategies LLC bought a new position in shares of Radius Health in the third quarter worth about $110,000. Jane Street Group LLC boosted its stake in Radius Health by 24.7% during the fourth quarter. Jane Street Group LLC now owns 10,043 shares of the biopharmaceutical company’s stock valued at $319,000 after buying an additional 1,988 shares during the last quarter. MANA Advisors LLC bought a new position in Radius Health during the fourth quarter valued at approximately $347,000. Teacher Retirement System of Texas bought a new position in Radius Health during the fourth quarter valued at approximately $353,000. Finally, Raymond James & Associates boosted its stake in Radius Health by 44.5% during the fourth quarter. Raymond James & Associates now owns 15,224 shares of the biopharmaceutical company’s stock valued at $484,000 after buying an additional 4,692 shares during the last quarter.
NASDAQ:RDUS traded down $0.47 during mid-day trading on Friday, hitting $33.27. 921,286 shares of the company traded hands, compared to its average volume of 867,069. Radius Health has a one year low of $24.66 and a one year high of $49.16. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.96 and a current ratio of 5.04. The firm has a market capitalization of $1,582.64, a PE ratio of -5.97 and a beta of 1.25.
ILLEGAL ACTIVITY WARNING: “-$1.40 Earnings Per Share Expected for Radius Health (RDUS) This Quarter” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://weekherald.com/2018/04/20/1-40-earnings-per-share-expected-for-radius-health-rdus-this-quarter.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.